Patents by Inventor Michael F. Parker

Michael F. Parker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic inhibitors of PAD4
    Patent number: 9963448
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 8, 2018
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Michael F. Parker, Edward Beaumont, Lee Bowles, Steve Bromidge, Sophie Cooper, Elise Gadouleau, Laura Gleave, Philip Kerry, Adrian Kotey, Thomas Krulle, Cristina Lecci, Pui Loke, Mirco Meniconi, Nat Monck, Carl North, Jordan Palfrey, Shelley Parrott, Mark Ridgill, Heather Tye
  • Oxazolidinones as modulators of mGluR5
    Patent number: 9688669
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: June 27, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew P. Degnan, Darrell Maxwell, Matthew D. Hill, Haiquan Fang, Michael F. Parker, Fukang Yang, Joanne J. Bronson, John E. Macor
  • BICYCLIC INHIBITORS OF PAD4
    Publication number: 20170166565
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: December 9, 2016
    Publication date: June 15, 2017
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Michael F. Parker, Edward Beaumont, Lee Bowles, Steve Bromidge, Sophie Cooper, Elise Gadouleau, Laura Gleave, Philip Kerry, Adrian Kotey, Thomas Krulle, Cristina Lecci, Pui Loke, Mirco Meniconi, Nat Monck, Carl North, Jordan Palfrey, Shelley Parrott, Mark Ridgill, Heather Tye
  • OXAZOLIDINONES AS MODULATORS OF MGLUR5
    Publication number: 20160237072
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: October 6, 2014
    Publication date: August 18, 2016
    Inventors: Andrew P. Degnan, Darrell Maxwell, Matthew D. Hill, Haiquan Fang, Michael F. Parker, Fukang Yang, Joanne J. Bronson, John E. Macor
  • Oxazolidinones as modulators of mGluR5
    Patent number: 8691821
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: April 8, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew P. Degnan, Hong Huang, Lawrence B. Snyder, Fukang Yang, Kevin W. Gillman, Michael F. Parker
  • ?-(N-sulfonamido)acetamide derivatives as ?-amyloid inhibitors
    Patent number: 8513253
    Abstract: There is provided a series of novel ?-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: August 20, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael F. Parker, Katharine E. McElhone, Robert A. Mate, Joanne J. Bronson, Yonghua Gai, Carl P. Bergstrom, Lawrence R. Marcin, John E. Macor
  • Oxazolidinones as Modulators of MGLUR5
    Publication number: 20120283264
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: November 2, 2011
    Publication date: November 8, 2012
    Inventors: Andrew P. Degnan, Hong Huang, Lawrence B. Snyder, Fukang Yang, Kevin W. Gillman, Michael F. Parker
  • Substituted heterocyclic ethers and their use in CNS disorders
    Patent number: 8071778
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: December 6, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael F. Parker, Joanne J. Bronson, Mark V. Silva, Kevin W. Gillman
  • Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors
    Publication number: 20110105485
    Abstract: There is provided a series of novel ?-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.
    Type: Application
    Filed: July 21, 2010
    Publication date: May 5, 2011
    Inventors: Michael F. Parker, Katharine E. McElhone, Robert A. Mate, Joanne J. Bronson, Yonghua Gai, Carl P. Bergstrom, Lawrence R. Marcin, John E. Macor
  • ?-(N-sulfonamido)acetamide derivatives as ?-amyloid inhibitors
    Patent number: 7786122
    Abstract: There is provided a series of novel ?-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: August 31, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael F. Parker, Katharine E. McElhone, Robert A. Mate, Joanne J. Bronson, Yonghua Gai, Carl P. Bergstrom, Lawrence R. Marcin, John E. Macor
  • Substituted Heterocyclic Ethers and Their Use in CNS Disorders
    Publication number: 20090030040
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Application
    Filed: January 25, 2008
    Publication date: January 29, 2009
    Inventors: Michael F. Parker, Joanne J. Bronson, Mark V. Silva, Kevin W. Gillman
  • SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS
    Publication number: 20080027056
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Application
    Filed: July 24, 2007
    Publication date: January 31, 2008
    Inventors: Michael F. Parker, Joanne J. Bronson, Mark V. Silva, Kevin W. Gillman
  • ?-(N-sulfonamido)acetamide derivatives as ?-amyloid inhibitors
    Patent number: 7300936
    Abstract: There is provided a series of novel ?-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: November 27, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael F. Parker, Katharin E. McElhone, Robert A. Mate, Joanne J. Bronson, Yonghua Gai, Carl P. Bergstrom, Lawrence R. Marcin, John E. Macor
  • Antiamyloid phenylsulfonamides: N-alkanol derivatives
    Patent number: 6989399
    Abstract: A series of N-alkanol-N-phenyl benzenesulfonamide and related derivatives of the Formula I are disclosed, wherein R1, R2, R3, X, and Y are defined herein. The compounds are inhibitors of ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions characterized by aberrant extracellular deposition of amyloid. Pharmaceutical compositions and methods of treatment are also disclosed.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: January 24, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: David W. Smith, Michael F. Parker
  • Sulfonamide compounds and uses thereof
    Patent number: 6967196
    Abstract: In accordance with the present invention, there is provided a novel class of sulfonamide compounds. Compounds of the invention contain a core sulfonamide group. Variable moieties connected to the sulfur atom and nitrogen atom of the sulfonamide group include substituted or unsubstituted hydrocarbyl moieties, substituted or unsubstituted heterocycle moieties, polycyclic moieties, halogen, alkoxy, ether, ester, amide, sulfonyl, sulfonamidyl, sulfide, carbamate, and the like. Invention compounds are capable of a wide variety of uses. For example sulfonamide compounds can act to modulate production of amyloid ? protein and are useful in the prevention or treatment of a variety of diseases. Pharmaceutical compositions containing invention compounds are also provided. Such compositions have wide utility for the prevention or treatment of a variety of diseases.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: November 22, 2005
    Assignees: Bristol-Myers Squibb Company, Merck & Co. Inc.
    Inventors: David W. Smith, Benito Munoz, Kumar Srinivasan, Carl P. Bergstrom, Prasad V. Chaturvedula, Milind S. Deshpande, Daniel J. Keavy, Wai Yu Lau, Michael F. Parker, Charles P. Sloan, Owen B. Wallace, Henry Hui Wang
  • Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors
    Publication number: 20040127494
    Abstract: There is provided a series of novel &agr;-(N-sulfonamido)acetamide compounds of the Formula (I) 1
    Type: Application
    Filed: December 20, 2002
    Publication date: July 1, 2004
    Inventors: Michael F. Parker, Katharine E. McElhone, Robert A. Mate, Joanne J. Bronson, Yonghua Gai, Carl P. Bergstrom, Lawrence R. Marcin, John E. Macor
  • Antiamyloid phenylsulfonamides: N-alkanol derivatives
    Publication number: 20040097572
    Abstract: A series of N-alkanol-N-phenyl benzenesulfonamide and related derivatives of the Formula I are disclosed, 1
    Type: Application
    Filed: July 24, 2003
    Publication date: May 20, 2004
    Inventors: David W. Smith, Michael F. Parker
  • Benzopyran derivatives as melatonergic agents
    Patent number: 6060506
    Abstract: Novel derivatives of benzopyran are provided which are useful as melatonergic agents.
    Type: Grant
    Filed: July 13, 1999
    Date of Patent: May 9, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: John D. Catt, Graham Johnson, Daniel J. Keavy, Ronald J. Mattson, Michael F. Parker, Katherine S. Takaki, Joseph P. Yevich
  • Carrier for ice cream cones and the like
    Patent number: 5996802
    Abstract: A plurality of ice cream cone nesting sites (14) are formed on the base wall (12,12') of a carrier (10,10'). Each nesting site is formed by a nesting wall configured as a truncated cone with its diameter decreasing as the distance from the base wall increases. The bottom wall is spaced above a supporting surface on which the carrier may be placed by feet (22,22') extending downwardly from the bottom wall to facilitate grasping and handling. A lip (28) may be formed around the outer perimeter of the bottom wall to provide spill containment and to enhance gripping of the carrier.
    Type: Grant
    Filed: October 10, 1998
    Date of Patent: December 7, 1999
    Inventors: Michael F. Parker, Emma I. Parker
  • Benzodioxa alkylene ethers as melatonergic agents
    Patent number: 5981571
    Abstract: Novel derivatives of benzodioxa alkylene ethers are provided which are useful as melatonergic agents.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: November 9, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: John D. Catt, Graham Johnson, Daniel J. Keavy, Ronald J. Mattson, Michael F. Parker, Katherine S. Takaki, Joseph P. Yevich